Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M201,495Revenue $M51,584Net Margin (%)20.9Z-Score2.7
Enterprise Value $M205,451EPS $3.2Operating Margin %27.0F-Score5
P/E(ttm))19.8Cash Flow Per Share $3.5Pre-tax Margin (%)27.0Higher ROA y-yN
Price/Book2.610-y EBITDA Growth Rate %3.2Quick Ratio2.5Cash flow > EarningsY
Price/Sales4.15-y EBITDA Growth Rate %8.5Current Ratio2.9Lower Leverage y-yN
Price/Cash Flow7.2y-y EBITDA Growth Rate %1.9ROA % (ttm)6.1Higher Current Ratio y-yN
Dividend Yield %3.3Insider Buy (3m)0ROE % (ttm)13.6Less Shares Outstanding y-yY
Payout Ratio %63.0Shares Outstanding M6,301ROI % (ttm)21.6Gross Margin Increase y-yN

Gurus Latest Trades with PFE

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
PFEIrving Kahn 2014-09-30 Reduce-0.59%$28.04 - $30.96
($29.58)
$ 31.948%Reduce -6.56%1,985,161
PFEMichael Price 2014-09-30 Reduce-0.22%$28.04 - $30.96
($29.58)
$ 31.948%Reduce -56.02%47,100
PFEJean-Marie Eveillard 2014-09-30 Reduce-0.16%$28.04 - $30.96
($29.58)
$ 31.948%Reduce -94.11%135,661
PFERay Dalio 2014-09-30 Reduce-0.02%$28.04 - $30.96
($29.58)
$ 31.948%Reduce -24.91%295,108
PFEHOTCHKIS & WILEY 2014-09-30 Sold Out -0.01%$28.04 - $30.96
($29.58)
$ 31.948%Sold Out0
PFEVanguard Health Care Fund 2014-06-30 Add0.62%$29.02 - $32.4
($30.05)
$ 31.946%Add 105.23%14,934,022
PFEJoel Greenblatt 2014-06-30 Add0.27%$29.02 - $32.4
($30.05)
$ 31.946%Add 71.59%1,741,314
PFECharles Brandes 2014-06-30 Add0.12%$29.02 - $32.4
($30.05)
$ 31.946%Add 5.78%6,075,460
PFERay Dalio 2014-06-30 Add0.06%$29.02 - $32.4
($30.05)
$ 31.946%Add 250.56%393,008
PFEMichael Price 2014-06-30 Reduce-0.97%$29.02 - $32.4
($30.05)
$ 31.946%Reduce -69.14%107,100
PFENWQ Managers 2014-06-30 Reduce-0.81%$29.02 - $32.4
($30.05)
$ 31.946%Reduce -31.07%6,363,006
PFEDodge & Cox 2014-06-30 Reduce-0.5%$29.02 - $32.4
($30.05)
$ 31.946%Reduce -23.73%48,902,097
PFEJean-Marie Eveillard 2014-06-30 Reduce-0.47%$29.02 - $32.4
($30.05)
$ 31.946%Reduce -70.71%2,303,762
PFEJohn Hussman 2014-06-30 Sold Out -0.04%$29.02 - $32.4
($30.05)
$ 31.946%Sold Out0
PFEHOTCHKIS & WILEY 2014-06-30 Reduce-0.01%$29.02 - $32.4
($30.05)
$ 31.946%Reduce -33.68%128,800
PFEIrving Kahn 2014-03-31 Add0.98%$29.66 - $32.75
($31.36)
$ 31.942%Add 11.22%2,112,819
PFEJoel Greenblatt 2014-03-31 Add0.38%$29.66 - $32.75
($31.39)
$ 31.942%Add 356.54%1,014,808
PFEJohn Hussman 2014-03-31 Buy 0.04%$29.66 - $32.75
($31.36)
$ 31.942%New holding, 17000 sh.17,000
PFEVanguard Health Care Fund 2014-03-31 Reduce-0.48%$29.66 - $32.75
($31.36)
$ 31.942%Reduce -40.13%7,276,622
PFENWQ Managers 2014-03-31 Reduce-0.39%$29.66 - $32.75
($31.39)
$ 31.942%Reduce -13.6%9,231,207
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

PFE is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
PFE David Dreman 2014-09-3015,04000.04+10.47%
PFE John Keeley 2014-09-3097,33900.06+8.35%
PFE Brian Rogers 2014-09-3012,737,1150.21.4+3.66%
PFE Charles Brandes 2014-09-306,257,0900.12.5+2.99%
PFE James Barrow 2014-09-3062,170,8810.992.5+2.76%
PFE Ken Fisher 2014-09-3031,702,4950.52+0.7%
PFE Vanguard Health Care Fund 2014-09-3014,934,0220.241.1
PFE Robert Bruce 2014-09-30452,0000.013.7
PFE Prem Watsa 2014-09-30235,00000.47
PFE Ruane Cunniff 2014-09-3010,96700-0.18%
PFE NWQ Managers 2014-09-306,338,4580.12-0.39%
PFE Dodge & Cox 2014-09-3047,604,9800.761.3-2.65%
PFE Ronald Muhlenkamp 2014-09-3039,49900.21-3.71%
PFE Irving Kahn 2014-09-301,985,1610.039.5-6.56%
PFE Joel Greenblatt 2014-09-301,622,0920.030.48-6.85%
PFE Mario Gabelli 2014-09-301,023,5810.020.16-7.29%
PFE Ray Dalio 2014-09-30295,10800.07-24.91%
PFE Michael Price 2014-09-3047,10000.17-56.02%
PFE Jean-Marie Eveillard 2014-09-30135,66100.01-94.11%
PFE HOTCHKIS & WILEY 2014-09-30000Sold Out
PFE Mark Hillman 2013-12-3123,98201.1
Premium Most recent portfolio changes are included for Premium Members only!


PFE: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
MADDALUNA ANTHONY JExecutive Vice President 2014-12-08Sell6,500$32-0.19view
HILL CHARLES HExecutive Vice President 2014-11-10Sell8,285$30.185.83view
DAMELIO FRANK AExecutive Vice President 2014-11-07Sell0$29.787.25view
YOUNG JOHN DGroup President 2014-11-07Sell21,600$29.896.86view
READ IAN CChairman & CEO 2014-10-30Sell67,500$29.767.33view
MADDALUNA ANTHONY JExecutive Vice President 2014-10-29Sell2,425$29.568.05view
OLSON LAURIE JExecutive Vice President 2014-06-12Sell36,275$29.538.16view
Germano Geno JGroup President 2014-06-02Sell30,000$29.687.61view
YOUNG JOHN DGroup President 2014-03-17Sell9,000$31.381.78view
PFIZER INC10% Owner 2014-03-12Buy272,727$11190.36view

Press Releases about PFE :

    Quarterly/Annual Reports about PFE:

      News about PFE:

      Articles On GuruFocus.com
      Pfizer Spreading Its Wings Into A New Domain Of Life Sciences Dec 09 2014 
      Zoetis in a Growing Global Animal Health Industry Dec 03 2014 
      Guru Ken Fisher’s Top Five Quarterly Stocks Nov 16 2014 
      Ackman’s Pershing Group Buys Stake in Zoetis Nov 13 2014 
      Activist Bill Ackman Buys Big Stake In Animal Healthcare Company Zoetis Nov 12 2014 
      The Importance of Capital Intensity and Thoughts From Einhorn Oct 31 2014 
      Johnson & Johnson Fairly Valued – I Will Bet on It Oct 30 2014 
      My 5 Favorite Stocks With Dividend Growth Of The Week Oct 27 2014 
      Guru Stocks at 52-Week Lows: GOOG, PFE, UN, E, MTU Oct 20 2014 
      10 Stocks With The Highest Share Buyback Volume In 2014 Oct 03 2014 


      More From Other Websites
      Holiday Hikes Dec 19 2014
      United Therapeutics Lung Drug Keeps Going And Going Dec 19 2014
      Pfizer Reports Statistically Significant Results for Nerve-Pain Treatment Dec 18 2014
      Pfizer Partners With Young Little Known Biotech For Products With Huge Potential Value Dec 18 2014
      Pfizer Reports Top-Line Results From a Phase 3 Study Evaluating Pregabalin Controlled-Release... Dec 18 2014
      8:00 am Pfizer announces top-line results from a double-blind Phase 3 study evaluating pregabalin;... Dec 18 2014
      Pfizer Reports Top-Line Results From a Phase 3 Study Evaluating Pregabalin Controlled-Release... Dec 18 2014
      Pfizer Initiates Phase 2 Study of PF-06252616 in Duchenne Muscular Dystrophy Dec 17 2014
      Pfizer Ponies Up to Develop Long-acting Growth Hormone Dec 16 2014
      Pfizer Invites Public to View and Listen to Webcast of January 27 Conference Call with Analysts Dec 16 2014
      Pfizer Invites Public to View and Listen to Webcast of January 27 Conference Call with Analysts Dec 16 2014
      Meningococcal Meningitis Survivor and TV Personality Amy Purdy and Pfizer Launch Take Action Against... Dec 16 2014
      Jacobs Designs Award-Winning Facility for Pfizer Dec 16 2014
      Meningococcal Meningitis Survivor and TV Personality Amy Purdy and Pfizer Launch Take Action Against... Dec 16 2014
      Pfizer Announces Palbociclib PALOMA-1 Data Published in The Lancet Oncology Dec 15 2014
      Pfizer Announces Palbociclib PALOMA-1 Data Published in The Lancet Oncology Dec 15 2014
      Business events scheduled for Tuesday Dec 15 2014
      Business events scheduled for Tuesday Dec 15 2014
      Pfizer, OPKO Health partner on growth-hormone treatment Dec 15 2014
      Pfizer, OPKO Health Partner on Growth-Hormone Treatment Dec 15 2014

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      SEENSCO
      ReplySEENSCO - 6 months ago
      PFE is trading at the low end of our short-term valuation range ($29-$36) and significantly below our Fair Value estimate of $42.41.
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK